Biopharmaceutical Revenues: 100% (2025)

TOP 3 Markets:

1. China: approx. 70%
2. USA: approx. 15%
3. Europe: approx. 10%

Innovent Biologics, Inc. generates its revenues entirely from the biopharmaceutical industry. The company mainly focuses on the development and commercialization of innovative drugs, particularly in the field of oncology.

The largest market for Innovent Biologics is China, where the company achieves a significant portion of its revenue due to its strong local presence and strategic partnerships. The expansion into international markets such as the USA and Europe has also gained importance, as reflected in the revenue shares.

Production sites of Innovent Biologics, Inc.:

1. Suzhou, China
2. Hangzhou, China

Innovent Biologics, Inc. mainly produces its biopharmaceutical products in China. The main production facility is located in Suzhou, where the company operates a state-of-the-art plant specialized in the manufacturing of biological drugs. In addition, Innovent has another production site in Hangzhou, which is also used for the production and development of biopharmaceutical products.

These production sites are strategically important for the company to meet the demand both in the domestic and international markets. Innovent continuously invests in expanding and modernizing its production capacities to meet the increasing requirements and ensure the quality of its products.

Focus on R&D Investments: 30% of revenue (2024)
Expansion of Product Portfolio: 5 new products in the pipeline (2025)
International Expansion: Entry into 3 new markets (2025)

Innovent Biologics, Inc. places a strong emphasis on research and development by investing a significant portion of its revenue in this area. This enables the continuous development of new and innovative products that complement and expand the existing portfolio.

The company plans to launch five new products in the coming years, which are currently in the pipeline. These products are intended to strengthen existing therapeutic areas and explore new markets.

In addition, Innovent is pursuing a strategy of international expansion by entering three new markets. This expansion is aimed at strengthening the company's global presence and tapping into new revenue sources. The combination of R&D investments, product expansion, and market expansion forms the basis for the future growth of Innovent Biologics.

Main raw materials: Biopharmaceutical active ingredients, cell cultures, reagents

Countries of origin: USA, Germany, China

Innovent Biologics, Inc. is a biopharmaceutical company specializing in the development and production of medications. For the production of its biopharmaceutical products, the company mainly imports biopharmaceutical active ingredients, cell cultures, and specialized reagents.

The USA and Germany are leading providers of high-quality biopharmaceutical materials and technologies, which is why Innovent Biologics imports from there. Additionally, the company also sources raw materials from China, as it has production facilities and local suppliers there that enable cost-effective supply.

The exact composition and origin may vary depending on the specific production requirements and regulatory conditions in the respective markets where Innovent operates.

Market Share in China: 10% in the Biopharma Sector (2024)
R&D Investments: 20% of Revenue (2024)
Patent Portfolio: Over 50 Active Patents (2024)

Innovent Biologics, Inc. has established itself in recent years as one of the leading players in the Chinese biopharma sector. With a market share of around 10% in China, the company demonstrates a strong presence in one of the world's largest markets for biopharmaceutical products.

The company consistently invests in research and development, with approximately 20% of revenue allocated to this area. These investments enable Innovent to develop and bring innovative therapies to the market, providing a significant competitive advantage.

In addition, Innovent has an extensive patent portfolio with over 50 active patents, further strengthening its position in the market and ensuring the protection of its innovations. Together, these factors give the company a robust competitive edge in the biopharma sector.

Institutional Investor Share: 68% (2025, estimated) Insider Buys/Sells: No significant changes (2025, estimated)

The institutional investor share in Innovent Biologics, Inc. is approximately 68%. This indicates a high level of trust from institutional investors in the company, which is often seen as a positive signal for the company's stability and growth potential.

In 2025, there were no significant insider buys or sells, suggesting that the management and insiders have a stable assessment of the current company situation. This can be interpreted as a sign that no drastic changes in the company's value are expected.

Market share of Innovent Biologics: 4.5% (estimated, 2025)

Top competitors and their market shares:

1. Roche Holding AG: 12.0%
2. Novartis AG: 10.5%
3. AstraZeneca PLC: 9.0%
4. Bristol-Myers Squibb: 8.0%
5. Pfizer Inc.: 7.5%
6. Merck & Co., Inc.: 7.0%
7. Sanofi: 6.5%
8. Johnson & Johnson: 5.5%
9. Innovent Biologics, Inc.: 4.5%
10. Eli Lilly and Company: 4.0%

Moat of Innovent Biologics:

Innovent Biologics has built a certain moat through its strong focus on the Chinese market and partnerships with international pharmaceutical companies. The company benefits from its ability to produce cost-effective biopharmaceutical products and has a robust pipeline of drugs in various stages of development.

However, compared to major international competitors, Innovent's moat is less pronounced. Companies like Roche and Novartis have more extensive research and development resources, a larger global presence, and established brands that give them a significant advantage.

Innovent Biologics could strengthen its moat through further innovations and strategic partnerships. Focusing on specific niche markets and adapting to local market needs could also help strengthen its competitive position.

Revenue Growth: 25% (2024) Research and Development Expenses: 30% of revenue (2024) Market Share in China: 15% in the Oncology sector (2024)

Innovent Biologics, Inc. achieved an impressive revenue growth of 25% in 2024, attributed to the successful launch of new drugs and expansion into international markets. The company is heavily investing in research and development, with expenses accounting for 30% of revenue. This indicates a strong pipeline of future products that have the potential to further drive growth.

The 15% market share in the Oncology sector in China demonstrates the company's strong position in one of the world's largest healthcare markets. This market position could be further strengthened through strategic partnerships and the introduction of new therapies.

In summary, due to its strong revenue growth, high investments in research and development, and solid market position in China, Innovent Biologics could be a promising investment. However, potential investors should also keep an eye on the risks associated with developing new drugs and the regulatory landscape.

Dividend payment: No dividend (2025)

Innovent Biologics, Inc. has not paid any dividends so far. The company is strongly focused on research and development in the field of biotechnology, which typically involves high investments.

In the biotechnology industry, it is not uncommon for companies to reinvest profits to expand their product pipeline and develop innovative therapies. Therefore, it is unlikely that Innovent Biologics will pay a dividend in the near future as long as the focus remains on growth and expansion.